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Among tuberculosis (TB) patients, acquired resistance to 
anti-TB drugs represents a failure in the treatment pathway. 
To improve diagnosis and care for patients with drug-resis-
tant TB, we examined the epidemiology and risk factors as-
sociated with acquired drug resistance during 2000–2015 
among TB patients in England, Wales, and Northern Ire-
land. We found acquired resistance in 0.2% (158/67,710) of 
patients with culture-confirmed TB. Using multivariate logis-
tic regression, we identified the following factors associated 
with acquired drug resistance: having pulmonary disease; 
initial resistance to isoniazid, rifampin, or both; a previous 
TB episode; and being born in China or South Africa. Treat-
ment outcomes were worse for patients with than without 
acquired resistance. Although acquired resistance is rare 
in the study area, certain patient groups are at higher risk. 
Identifying these patients and ensuring that adequate re-
sources are available for treatment may prevent acquisition 
of resistance, thereby limiting transmission of drug-resistant 
strains of mycobacteria.
In 2015, of an estimated 10.4 million incident tubercu-losis (TB) cases worldwide, 4.6% were multidrug re-
sistant (MDR) (1). MDR TB is a major challenge for TB 
control, and strategies to reduce it underpin the 3 pillars of 
the World Health Organization End TB Strategy (1,2). The 
main challenges are preventing acquisition of drug resis-
tance and ensuring early detection and appropriate treat-
ment to prevent further transmission of drug-resistant TB. 
As a result, in the Collaborative TB Strategy for England 
2015–2020, reducing drug-resistant TB is a key area of ac-
tion for ensuring that adequate resources needed to prevent 
and treat MDR TB exist (3).
In the United Kingdom, the proportion of MDR TB 
cases has remained stable over the past decade, account-
ing for 1.5% of all culture-confirmed TB cases in 2015, 
similar to the proportions in other low-incidence countries, 
including the United States (1.2%) and France (1.7%) (1,4). 
Other drug-resistance profiles affect treatment and include 
isoniazid resistance without MDR TB (attributable to 5.6% 
of TB cases in the United Kingdom) and rifampin resistance 
without MDR TB (accounts for only 0.2% of TB cases) 
(4). In addition to the clinical challenges of long and com-
plex treatment regimens often involving adverse reactions 
for patients with drug-resistant TB, social risk factors and 
concurrent conditions may complicate treatment and wors-
en outcomes (5).
Drug-resistant TB can arise in 2 ways: through trans-
mission of a drug-resistant strain (primary drug resistance) 
or through acquisition of drug resistance (acquired drug 
resistance, in which a person is infected by a strain that 
is initially sensitive to a particular drug but resistance to 
that drug evolves later) (6,7). Acquired drug resistance can 
result from inadequate treatment, which may be caused 
by interruptions to receipt of the full drug regimen (8,9). 
Treatment interruption because of drug unavailability, poor 
adherence, or side effects contributes to insufficient dosing 
or treatment duration (7).
Acquired drug resistance has consequences for pub-
lic health through the spread of drug-resistant TB, poorer 
health outcomes for patients, and cost to the healthcare sys-
tem (10–12). Understanding the risk factors associated with 
acquired resistance could improve prevention measures. 
Our objective for this study was to describe the epidemiol-
ogy of TB among patients in England, Wales, and Northern 
Ireland, in whom drug resistance was acquired while they 
were receiving treatment. We also examined the frequency 
and timing of acquired resistance, sociodemographic and 
clinical factors associated with acquired resistance, and 
treatment outcomes for these patients.
Methods
Study Population and Definitions
We conducted a retrospective cohort study of all pa-
tients with culture-confirmed TB (pulmonary and 
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extrapulmonary-only disease) notified to the Enhanced TB 
Surveillance System in England, Wales, and Northern Ire-
land during 2000–2015 for whom initial drug-susceptibil-
ity testing (DST) results for at least isoniazid and rifampin 
were available. Acquired resistance was defined as a sen-
sitive DST result for a drug on 1 isolate and a subsequent 
resistant DST result for the same drug on another. We 
excluded TB patients known to have not started treatment.
Laboratory Methods and Data
The United Kingdom follows the global guidance that 
samples should be obtained for culture and DST at least 
every 1, 2, and 5 months, whereas samples from patients 
whose TB was initially MDR TB should be obtained 
every month (13–15). Samples are collected more often 
from patients who do not clinically respond to treatment 
as expected.
Samples from all presumptive TB patients are sent 
from hospital laboratories in England, Wales, and Northern 
Ireland to a Mycobacterium reference laboratory for spe-
ciation, phenotypic DST, and 24-loci MIRU-VNTR (my-
cobacterial interspersed repetitive unit–variable-number 
tandem repeat) strain typing (16). Results from culture-
confirmed M. tuberculosis complex samples were routinely 
extracted from laboratory information management sys-
tems and imported into the Enhanced TB Surveillance Sys-
tem. The strain lineage was derived from the MIRU-VNTR 
strain types for cases notified during 2010–2015 (17). The 
reference laboratories routinely performed DST for first-
line drugs (isoniazid, rifampin, ethambutol, and pyrazin-
amide) on all M. tuberculosis complex samples. DST for 
second-line injectables (amikacin, capreomycin, and kana-
mycin) and fluoroquinolones (ofloxacin, moxifloxacin, and 
ciprofloxacin) was performed on rifampin-resistant isolates 
or at the request of the treating clinician. DST results for 
ethambutol and pyrazinamide can vary (18), which was 
mitigated at the reference laboratory by repeat testing of 
isolates that initially showed resistance.
Data Collection
Clinical and demographic data for TB patients were col-
lected in the Enhanced TB Surveillance System and proba-
bilistically matched to M. tuberculosis complex isolates 
(5,19). We analyzed individually the 8 countries of birth 
with the highest number of TB patients with acquired drug 
resistance. Data on patient social risk factors (current or 
history of drug misuse, alcohol misuse, homelessness, and 
imprisonment) were available for cases notified during 
2010–2015. Treatment outcome was reported for cases no-
tified during 2001–2013.
Descriptive Analyses
We described cases with acquired resistance by year of 
notification. The proportion of TB patients in whom resis-
tance to each drug was acquired was calculated from the 
number of TB patients for whom DST results for that drug 
were available. TB patients with acquired resistance were 
categorized according to their initial drug resistance pro-
file (Table 1) and acquired drug resistance profile (Table 
2) throughout the analysis. Each new identification of re-
sistance in different cultures from the same patient was de-
fined as an episode of acquired resistance.
The time to diagnosis of acquired resistance (referred 
to as acquiring drug resistance) was calculated from the 
treatment start date to the specimen collection date for 
the first DST result that showed evidence of acquired 
resistance. The time to diagnosis of acquired resistance 
was calculated for TB patients who acquired resistance 
after starting an appropriate treatment; therefore, we ex-
cluded from this section of analysis those patients who 
acquired resistance before starting an appropriate treat-
ment or who did not have a known start date for appropri-
ate treatment.
Statistical Analyses
We compared clinical and demographic data among pa-
tients with any acquired resistance with those without ac-
quired resistance by using univariable logistic regression 
to calculate odds ratios (ORs). We created a multivariable 
model by using a forward stepwise approach, including 
factors with p<0.5 from the univariable analysis and us-
ing data from the entire cohort (2000–2015) (model 1). We 
created a second multivariable model limiting the data to 
2010–2015 because of the availability of social risk factors 
and strain type lineage data (model 2).
To account for the variability in resistance results for 
ethambutol and pyrazinamide, we performed a sensitiv-
ity analysis by excluding from logistic regression model 
1 those TB patients who acquired resistance to only eth-
ambutol and pyrazinamide. Because of low numbers and 
loss of power, we did not perform a sensitivity analysis on 
model 2.
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Table 1. Initial drug resistance profiles used to categorize resistance to anti-TB drugs* 
Initial drug resistance profile Description of drug-resistance profile† 
Drug sensitive Initially sensitive to both isoniazid and rifampin 
Isoniazid resistance without MDR TB Initially resistant to isoniazid and sensitive to rifampin 
Rifampin resistance without MDR TB Initially resistant to rifampin and sensitive to isoniazid 
MDR TB Initially resistant to both isoniazid and rifampin 
*MDR, multidrug-resistant; TB, tuberculosis. 
†These profiles refer specifically to resistance to isoniazid and/or rifampin, but resistance to other drugs may also be present. 
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We used χ2 tests to compare treatment outcomes 
among those with and without acquired drug resistance. 
All analyses were conducted by using Stata version 13.1 
(StataCorp LLC, College Station, TX, USA).
Results
During 2000–2015, a total of 69,300 culture-confirmed 
TB cases were notified in England, Wales, and Northern 
Ireland; among these, 99.1% (68,686/69,300) had DST 
results for at least isoniazid and rifampin (Figure 1). We 
excluded 976 TB patients known to have not started treat-
ment. Overall, 0.2% (158/67,710) of culture-confirmed 
TB patients with DST results acquired drug resistance. 
The median number of TB patients with acquired resis-
tance per year was 11 (range 0–21) (Figure 2). The num-
ber of TB patients with acquired resistance increased over 
time (p = 0.002).
Among patients tested for each drug, the highest 
numbers acquired resistance to rifampin (50/67,710), 
isoniazid (48/67,710), ethambutol (32/67,645), and 
pyrazinamide (28/67,061). The highest percentage 
of patients had acquired resistance to ethionamide 
(1.1%, 15/1,345) and prothionamide (0.8%, 15/1,345) 
(Figure 3).
Initial Drug-Resistance Profile
Isolates from most TB patients with acquired resistance 
were initially sensitive to both isoniazid and rifampin 
(46.8%, 74/158) (Table 3). Resistance to additional drugs 
was acquired by 0.1% (74/62,795) of TB patients with 
isolates initially sensitive to isoniazid and rifampin, 0.9% 
(34/3,864) of TB patients with isoniazid resistance and 
without rifampin resistance, 1.5% (3/203) of TB patients 
with rifampin resistance and without isoniazid resistance, 
and 5.5% (47/848) of MDR TB patients. 
For 44 TB patients, acquired resistance resulted in 
MDR TB; among these patients, initial isolates from 20 
were sensitive to both isoniazid and rifampin, 22 were re-
sistant to isoniazid without MDR TB, and 2 were resistant 
to rifampin without MDR TB. A total of 67 TB patients 
acquired resistance without it being MDR TB (initial or ac-
quired); the highest proportion was resistant to isoniazid 
(32.8%, 22/67), followed by streptomycin (22.4%, 15/67) 
and pyrazinamide (14.9%, 10/67).
Episodes of Acquired Resistance
Resistance was acquired to 1–6 drugs; most (69.0%, 
109/158) resistance was to only 1 drug, 19.6% (31/158) 
to 2 drugs, and 6.3% (10/158) to >3 drugs. Of those who 
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Figure 1. Process used to 
select tuberculosis (TB) patients 
with acquired drug resistance 
among all TB patients with 
culture-confirmed TB, England, 
Wales, and Northern Ireland, 
2000–2015.
 
Table 2. Description of acquired drug resistance profiles used to categorize resistance to anti-TB drugs* 
Acquired drug resistance profile Description of drug-resistance profile 
TB patients who did not have MDR TB before or after acquiring 
resistance 
Initially sensitive to isoniazid, rifampin, or both and may have 
acquired resistance to either isoniazid or rifampin but not both or 
may have acquired resistance to other anti-TB drug(s). 
TB patients who acquired resistance that resulted in MDR TB  Initially sensitive to isoniazid, rifampin, or both and acquired 
resistance to isoniazid, rifampin, or both to have MDR TB. 
Patients with initial MDR TB and acquired resistance to additional 
drugs 
Initially resistant to at least isoniazid and rifampin and on 
subsequent culture acquired resistance to other anti-TB drug(s). 
*MDR, multidrug-resistant; TB, tuberculosis. 
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acquired resistance to >2 drugs, 65.3% (32/49) acquired re-
sistance in 1 episode, 28.6% (14/49) over 2 episodes, and 
6.1% (3/49) over 3 episodes. The median time between 
the first and second episode for those who had at >2 epi-
sodes was 3.5 months (interquartile range [IQR] 2.4–11.9 
months), and the median time between the second and 
third episode for those who had 3 repeat episodes was 5.3 
months (IQR 4.7 months–2 years).
Time between Starting Treatment and  
Acquiring Resistance
Ten MDR TB patients acquired resistance between start-
ing an initial regimen and switching to the appropriate 
regimen for drug resistance. These patients acquired resis-
tance to ethambutol (4), pyrazinamide (1), ethionamide (4), 
and prothionamide (1).
A total of 136 TB patients acquired resistance after 
starting an appropriate treatment regimen; median time 
between starting treatment and acquiring resistance to 
>1 drug or to the first drug was 3.4 months (IQR 1.5–8.3 
months). Resistance was acquired by 12% (17/136) of pa-
tients 1 year after starting treatment (Table 4).
Most (64.1%, 25/39) TB patients in whom acquired 
resistance developed into MDR TB had received treatment 
for >6 months before resistance was acquired (Table 4). 
Conversely, 76.2% (32/42) of MDR TB patients in whom 
resistance to additional drugs was acquired had received 
treatment <6 months before acquiring additional resistance.
Risk Factors for Acquiring Resistance
Among TB patients with acquired resistance, most 
were 15–44 years of age (70.3%, 111/158), were male 
(59.5%, 94/158), were foreign born (75.2%, 115/153), 
and had pulmonary disease (82.9%, 131/158). A previ-
ous TB diagnosis was reported for 23% (32/141). Among 
those who had acquired resistance >1 year after starting 
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Figure 2. Number and proportion 
of tuberculosis patients with 
acquired drug resistance, by 
year, England, Wales, and 
Northern Ireland, 2000–2015.
Figure 3. Number and proportion 
of tuberculosis patients with 
acquired drug resistance, by 
drug, England, Wales, and 
Northern Ireland, 2000–2015. 
AMK, amikacin; AZM, 
azithromycin; CIP, ciprofloxacin; 
CLR, clarithromycin; 
CPM, capreomycin; CSN, 
cycloserine; EMB, ethambutol; 
ETH, ethionamide; KAN, 
kanamycin; INH, isoniazid; MXF, 
moxifloxacin; OXF, ofloxacin; 
PAS, para-aminosalicylic 
acid (bacteriostatic); PTO, 
prothionamide; PZA, 
pyrazinamide; RIF, rifampin; 
RFB, rifabutin;  
STR, streptomycin.
RESEARCH
treatment, the demographic profile differed: most were 
female (58.8%, 10/17) and born in the United Kingdom 
(66.7%, 5/15), and although they were similar in age, most 
(58.8%, 10/17) were 15–44 years of age. Among TB pa-
tients notified during 2010–2015, a total of 28% (18/65) 
had >1 social risk factor.
Multivariable model 1 showed that acquired resistance 
was more likely among TB patients with than without the 
following characteristics: pulmonary disease (adjusted OR 
[aOR]  2.1, 95% CI 1.3–3.3); initial resistance to isonia-
zid (aOR 6.2, 95% CI 3.9–10.0), rifampin (aOR 10.8, 95% 
CI 3.3–35.3), or both (aOR 41.8, 95% CI 27.0–64.7); and 
a previous TB episode (aOR 2.3, 95% CI 1.5–3.5) (Table 
5). TB patients born in China were 3.4 times more likely 
(95% CI 1.3–8.8) and those born in South Africa were 2.8 
times more likely (95% CI 1.1–7.5) to acquire resistance 
than those born in the United Kingdom; patients born in 
India were less likely to acquire resistance than those born 
in the United Kingdom (aOR 0.4, 95% CI 0.2–0.8). Sensi-
tivity analysis of multivariable model 1, which excluded 
TB patients who acquired resistance to ethambutol only, 
pyrazinamide only, or both, showed trends of demographic 
characteristics that were more or less likely to be associ-
ated with acquired resistance similar to those in the original 
model (Table 6).
Multivariable model 2, which included social risk fac-
tors and strain type lineage, showed that acquisition of drug 
resistance was more likely among TB patients with than 
without the following characteristics: age 45–64 years (aOR 
1.9, 95% CI 1.0–3.6); pulmonary disease (aOR 2.7, 95% CI 
1.2–6.0); and initial resistance to isoniazid (aOR 6.5, 95% 
CI 2.9–14.4), rifampin (aOR 14.7, 95% CI 1.8–1213.0), or 
both (aOR 77.3, 95% CI 39.1–152.8) (Table 7). Although a 
higher proportion of TB patients with (27.7%, 18/65) than 
without (11.6%, 2,632/22,795) acquired resistance had a so-
cial risk factor, after the other factors in model 2 were ad-
justed for, having a social risk factor was not significantly 
associated with acquiring resistance. No country of birth 
was significantly associated with acquired resistance, but 
TB patients born in India were less likely to acquire resis-
tance than those born in the United Kingdom (aOR 0.3, 95% 
CI 0.1–0.8). TB patients infected with a Beijing lineage M. 
tuberculosis strain (aOR 3.4, 95% CI 1.6–7.4) or M. bovis 
(aOR 10.3, 95% CI 2.1–49.8) were more likely to acquire 
drug resistance. Among this subpopulation of TB cases noti-
fied during 2010–2015, lineage and country of birth were 
collinear (p<0.001) and thus not included in the model.
Treatment Outcomes
Treatment was completed by a lower proportion of TB 
patients who did (61.4% [86/140]) than did not (79.9% 
[45,690/57,209]) acquire drug resistance (p<0.001), and 
the median duration of treatment was longer among those 
who did (19.2 months [IQR 12–30 months) than did not 
(6.2 months [IQR 6–8.8 months]) acquire drug resistance 
(Table 8). A higher proportion of TB patients with (7.1% 
[10/140]) than without (4.6% ([2,651/57,209]) acquired 
resistance died (p<0.001), but time to death was longer 
for those with acquired resistance (6.8 months [IQR 5.8 
months–2.1 years]) than for those without acquired resis-
tance (1.3 months [IQR 0.4–3.2 months]). Among TB pa-
tients with acquired resistance, outcomes were worse for 
those in whom MDR developed than for those with other 
categories of drug resistance (p = 0.03) (Table 8).
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Table 3. TB cases according to drug-resistance profile, England, Wales, and Northern Ireland, 2000–2015* 
Initial drug-resistance profile, no. patients with 
acquired drug resistance 
Acquired resistance and 
MDR TB developed 
later, no. (%) 
Initial MDR TB with 
additional resistance 
acquired later, no. (%) 
No MDR TB before or 
after acquiring resistance, 
no. (%) 
Drug sensitive, n = 74 20 (27.0) NA 54 (73.0) 
Isoniazid resistant without MDR, n = 34 22 (64.7) NA 12 (35.3) 
Rifampin resistant without MDR, n = 3 2 (66.7) NA 1 (33.3) 
MDR TB, n = 47 NA 47 (100) NA 
Total, n = 158 44 (27.8) 47 (29.7) 67 (42.4) 
*MDR, multidrug-resistant; NA, not applicable; TB, tuberculosis. 
 
 
 
Table 4. Number and proportion of TB cases, by time between treatment initiation and drug resistance acquisition and by acquired 
drug resistance categories, England, Wales, and Northern Ireland, 2000–2015* 
Time between treatment start 
and acquired resistance 
Acquired drug resistance category 
No MDR TB before or 
after acquiring resistance, 
no. (%) 
Acquired resistance and 
MDR TB developed 
later, no. (%) 
Initial MDR TB with 
additional resistance 
acquired later, no. (%) 
Total with 
acquired drug 
resistance, no. (%) 
<1 mo 20 (36.4) 2 (5.1) 5 (11.9) 27 (19.9) 
2 mo 10 (18.2) 0 13 (31.0) 23 (16.9) 
3 mo 8 (14.5) 3 (7.7) 4 (9.5) 15 (11.0) 
4–6 mo 6 (10.9) 9 (23.1) 10 (23.8) 25 (18.4) 
7–9 mo 4 (7.3) 8 (20.5) 5 (11.9) 17 (12.5) 
10 mo–1 y 4 (7.3) 7 (18.0) 1 (2.4) 12 (8.8) 
>1 y 3 (5.5) 10 (25.6) 4 (9.5) 17 (12.5) 
Total 55 (100) 39 (100) 42 (100) 136 (100) 
*MDR, multidrug-resistant; TB, tuberculosis. 
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Discussion
In England, Wales, and Northern Ireland, acquiring drug 
resistance while receiving TB treatment is rare (0.2% of 
cases) but more likely among those with pulmonary dis-
ease; with initial resistance to isoniazid, rifampin, or both; 
who experienced a previous TB episode; or who were born 
in China or South Africa. Our description of the character-
istics of TB patients provides useful insight into the care 
required for these patients.
For most (57.6%) of the TB patients in our study, ei-
ther their acquired resistance resulted in MDR TB or they 
initially had MDR TB and acquired additional resistance, 
thereby limiting treatment options. Our study demonstrates 
the value of identifying and preventing acquired drug re-
sistance in patients without MDR TB, one third of whom 
acquire resistance to isoniazid, one of the main drugs used 
in standard treatment. A study in China showed that ac-
quired drug resistance among any patients with culture-
confirmed TB was much higher (3.7%) than that for our 
study population (20). Studies from India have shown high 
rates of MDR TB among previously treated patients with 
drug-sensitive isolates, some of which would be accounted 
for by acquired resistance to the first-line drugs (21).
Most other studies from other low-incidence coun-
tries report on TB patients with MDR TB in whom 
further resistance to second-line drugs is acquired; for 
example, in the United States, drug resistance was ac-
quired by 5.0% of MDR TB patients, similar to the rate 
of 5.5% of MDR TB patients identified in our study 
(22–24). Numerous studies highlight the need for indi-
vidualized treatment regimens for patients with MDR 
TB (13,25,26). In the United Kingdom, the national 
TB control strategy advocates increasing resources to 
strengthen a multidisciplinary clinical advisory service 
that will ensure that MDR TB is treated effectively (3). 
Our study adds to the growing evidence for the need to 
more closely supervise and monitor MDR TB patients 
by regular use of DST for second-line drugs and the need 
to ensure that adequate resources are available to meet 
patient needs.
In our study, acquired resistance was more likely in TB 
patients with pulmonary disease and, if ineffectively treat-
ed, could lead to the transmission of drug-resistant strains. 
Another study found that the presence of pulmonary cavita-
tion increased the risk of acquiring resistance (23). In our 
study and others, acquired resistance was more likely in 
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Table 5. Univariable and multivariable logistic regression model 1 for acquired resistance to anti-TB drugs in England, Wales, and 
Northern Ireland, 2000–2015* 
Characteristic 
No acquired drug 
resistance, no. (%) 
Acquired drug 
resistance, no. (%) 
Univariable analysis 
 
Multivariable analysis 
OR (95% CI) p value OR (95% CI) p value 
Age, y 
    
 
  
 0–14  1,391 (2.1) 2 (1.3) 1.0  NA  NA NA 
 15–44  44,227 (65.5) 111 (70.3) 1.7 (0.4–7.1) 0.4  1.6 (0.4–6.7) 0.5 
 45–64  12,859 (19.0) 40 (25.3) 2.2 (0.5–9.0) 0.3  2.5 (0.6–10.7) 0.2 
 >65 9,071 (13.4) 5 (3.2) 0.4 (0.1–2.0) 0.2  0.6 (0.1–3.2) 0.5 
Sex 
    
 
  
 F 28,453 (42.2) 64 (40.5) 1.0  NA  NA NA 
 M 38,985 (57.8) 94 (59.5) 1.1 (0.8–1.5) 0.7  1.2 (0.8–1.6) 0.4 
Site of disease 
    
 
  
 Extrapulmonary only 24,217 (35.9) 27 (17.1) 1.0  NA  NA NA 
 Pulmonary with or without  
 extrapulmonary 
43,313 (64.1) 131 (82.9) 2.7 (1.8–4.1) <0.001  2.1 (1.3–3.3) 0.003 
Initial drug resistance 
    
 
  
 Drug sensitive 62,721 (92.9) 74 (46.8) 1.0  NA  NA NA 
 Isoniazid resistance  
 without MDR 
3,830 (5.7) 34 (21.5) 7.5 (5.0–11.3)  <0.001  6.2 (3.9–10.0) <0.001 
 Rifampin resistance  
 without MDR 
200 (0.3) 3 (1.9) 12.7 (4.0–40.7)  <0.001  10.8 (3.3–35.3) <0.001 
 MDR 801 (1.2) 47 (29.7) 49.7 (34.3–72.2)  <0.001  41.8 (27.0–64.7) <0.001 
Country of birth 
    
 
  
 United Kingdom 16,184 (26.3) 38 (25.7) 1.0 NA  NA NA 
 China 465 (0.8) 6 (4.1) 5.5 (2.3–13.1) <0.001  3.4 (1.3–8.8) 0.01 
 India 11,227 1(8.3) 11 (7.4) 0.4 (0.2–0.8) 0.01  0.4 (0.2–0.8) 0.01 
 Lithuania 238 (0.4) 9 (6.1) 16.1 (7.7–33.7) <0.001  1.8 (0.8–4.4) 0.2 
 Pakistan 7,696 (12.5) 15 (10.1) 0.8 (0.5–1.5) 0.6  0.9 (0.4–1.7) 0.6 
 Somalia 4,184 (6.8) 9 (6.1) 0.9 (0.4–1.9) 0.9  0.9 (0.4–1.9) 0.7 
 South Africa 759 (1.2) 5 (3.4) 2.8 (1.1–7.1) 0.03  2.8 (1.1–7.5) 0.04 
 Nigeria 1,324 (2.2) 4 (2.7) 1.3 (0.5–3.6) 0.6  0.8 (0.2–2.6) 0.7 
 Other 19,417 (31.6) 51 (34.5) 1.1 (0.7–1.7) 0.6  0.9 (0.6–1.5) 0.8 
Previous TB episode 
    
 
  
 No 54,346 (93.3) 109 (77.3) 1.0  NA  NA NA 
 Yes 3,910 (6.7) 32 (22.7) 4.0 (2.7–6.1) <0.001  2.3 (1.5–3.5) <0.001 
*MDR, multidrug-resistant; NA, not applicable; OR, odds ratio; TB, tuberculosis. 
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TB patients who had had a previous TB episode, which 
suggests that these cases were neither successfully treat-
ed nor cured during the previous TB episode, most likely 
because of previous compliance issues (23,27–29). These 
findings demonstrate the need to efficiently diagnose resis-
tance and ensure that appropriate drug regimens are pro-
vided and adhered to.
Our study also found that acquired resistance was 
more likely in TB patients born in China and South Af-
rica; however, this association was lost when strain lin-
eage was considered. This relationship between country 
of birth and lineage may be explained by the geographic 
stratification of M. tuberculosis complex lineages. There-
fore, the country of birth could instigate greater moni-
toring of TB treatment for patients in whom acquired 
resistance is more likely (e.g., those infected with Bei-
jing strains, who acquire MDR TB more readily [30,31]). 
Acquired resistance was more likely in patients with TB 
caused by M. bovis; and although the number of patients 
in our study was small, only 2 patients with acquired re-
sistance had TB caused by M. bovis, and both of these 
patients acquired resistance to isoniazid. This associa-
tion with M. bovis has also been shown by a study in the 
United States, where M. bovis was independently associ-
ated with acquiring resistance to isoniazid (32).
Our study indicated that resistance was acquired by 
a higher proportion of TB patients with than without a 
social risk factor. However, studies in other countries 
did not consistently find an association between acquired 
resistance and social risk factors (7,23,27). Our findings 
indicate that outcomes were poorer (e.g., death or loss to 
follow-up) among TB patients with than without acquired 
resistance. Similar results have been reported elsewhere 
(9,20,33–35). Acquisition of resistance occurred later in 
treatment among patients who acquired resistance that re-
sulted in MDR TB; one quarter acquired resistance >12 
months after starting treatment, and their outcomes were 
worse than those for patients with other types of acquired 
drug-resistance profiles. Treatment can continue beyond 
12 months for several reasons (e.g., initial drug resistance, 
acquired resistance, adherence issues, or clinical signs that 
the patient has not been cured), which by international re-
porting standards would be reported as treatment failed, 
but in the United Kingdom these patients are reported as 
still receiving treatment, and outcomes beyond 12 months 
are reported. Treatment failure has been shown to be 
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Table 6. Sensitivity analysis of univariable and multivariable logistic regression model 1 for acquired resistance to anti-TB drugs in 
England, Wales, and Northern Ireland, 2000–2015* 
Characteristic 
No acquired drug 
resistance, no. (%) 
Acquired drug 
resistance, no. (%) 
Univariable analysis 
 
Multivariable analysis 
OR (95% CI) p value aOR (95% CI) p value 
Age, y 
    
 
  
 0–14  1,392 (2.1) 1 (0.9) 1.0 (NA) NA  1.0 (NA) NA 
 15–44  44,263 (65.5) 75 (69.4) 2.4 (0.3–17.0) 0.4  2.4 (0.3–17.4) 0.4 
 45–64  12,871 (19.0) 28 (25.9) 3.0 (0.4–22.3) 0.3  3.0 (0.4–23.2) 0.3 
 >65 9,072 (13.4) 4 (3.7) 0.6 (0.1–5.5) 0.7  0.9 (0.1–7.8) 0.9 
Sex 
     
 
  
 F 28,476 (42.2) 41 (38.0) 1.0 (NA) NA  1.0 (NA) NA 
 M 39,012 (57.8) 67 (62.0) 1.2 (0.8–1.8) 0.4  1.4 (0.9–2.1) 0.2 
Site of disease 
    
 
  
 Extrapulmonary only 24,233 (35.9) 11 (10.2) 1.0 (NA) NA  1.0 (NA) NA 
 Pulmonary with or without  
 extrapulmonary 
43,347 (64.1) 97 (89.8) 4.9 (2.6–9.2) <0.001  3.0 (1.6–5.7) 0.001 
Initial drug resistance 
    
 
  
 Drug sensitive 62,740 (92.8) 55 (50.9) 1.0 (NA) NA  1.0 (NA) NA 
 Isoniazid resistance  
 without MDR 
3,839 (5.7) 25 (23.2) 7.4 (4.6–11.9) <0.001  6.5 (3.7–11.2) <0.001 
 Rifampin resistance  
 without MDR 
200 (0.3) 3 (2.8) 17.1 (5.3–55.1) <0.001  15.2 (4.6–50.2) <0.001 
 MDR 823 (1.2) 25 (23.2) 34.7 (21.5–55.9) <0.001  32.7 (18.9–56.8) <0.001 
Country of birth 
    
 
  
 United Kingdom 16,189 (26.3) 33 (33.0) NA  NA  1.0 (NA) NA 
 China 467 (0.8) 4 (4.0) 4.2 (1.5–11.9) 0.01  2.5 (0.8–7.7) 0.1 
 India 11,232 (18.2) 6 (6.0) 0.3 (0.1–0.6) 0.003  0.2 (0.1–0.6) 0.004 
 Lithuania 243 (0.4) 4 (4.0) 8.1 (2.8–23.0) <0.001  0.8 (0.2–2.8) 0.7 
 Pakistan 7,702 (12.5) 9 (9.0) 0.6 (0.3–1.2) 0.1  0.8 (0.4–1.7) 0.5 
 Somalia 4,190 (6.8) 3 (3.0) 0.4 (0.1–1.1) 0.1  0.4 (0.1–1.3) 0.1 
 South Africa 759 (1.2) 5 (5.0) 3.2 (1.3–8.3) 0.02  3.3 (1.2–8.8) 0.02 
 Nigeria 1,326 (2.2) 2 (2.0) 0.7 (0.2–3.1) 0.7  0.3 (0.04–2.1) 0.2 
 Other 19,43 (31.6) 34 (34.0 0.9 (0.5–1.4) 0.5  0.7 (0.4–1.2) 0.2 
Previous TB episode 
    
 
  
 No 54,379 (93.3) 76 (79.2) 1.0 (NA) NA  1.0 (NA) NA 
 Yes 3,922 (6.7) 20 (20.8) 3.6 (2.2–6.0) <0.001  2.2 (1.3–3.8) 0.01 
*aOR, adjusted OR; MDR, multidrug-resistant; NA, not applicable; OR, odds ratio; TB, tuberculosis. 
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associated with late emergence of acquired resistance 
(20), which is consistent with our findings. This evidence 
illustrates how acquired resistance impedes successful 
treatment outcomes.
Our study benefits from having a large national 
cohort followed over an extended period. In the Unit-
ed Kingdom, culture-positive results are routinely 
matched to case data, enabling the study of drug sus-
ceptibility combined with demographic and clinical 
factors. However, our study does have several limita-
tions. First, some local laboratories may process fol-
low-up cultures without sending the samples on to the 
Mycobacterium reference laboratories, leading to un-
derestimation of acquired resistance. It is also possible 
that patients with initial resistance (to isoniazid, to ri-
fampin, or MDR TB) may receive more frequent sam-
pling, enabling acquisition of resistance to be more read-
ily detected. Sampling may also differ by site of disease 
because obtaining multiple samples from patients with 
extrapulmonary disease may be more difficult. However, 
these situations are unlikely to occur commonly because 
failure to respond to treatment would prompt further 
sample collection. In addition, if there is a delay in col-
lecting samples because of missed/rescheduled appoint-
ments, the reported time to diagnosis of acquired resis-
tance may be longer than the actual time to diagnosis.
Although TB guidance in the United Kingdom recom-
mends collecting specimens when TB is suspected, and 
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Table 7. Univariable and multivariable logistic regression model 2 for acquired resistance to anti-TB drugs in England, Wales, and 
Northern Ireland, 2010–2015* 
Characteristic 
No acquired drug 
resistance, no. (%) 
Acquired drug 
resistance, no. (%) 
Univariable analysis 
 
Multivariable analysis 
OR (95% CI) p value aOR (95% CI) p value 
Age, y        
 0–14  467 (1.8 ) 0 NA NA  NA NA 
 15–44 17,119 (64.6) 48 (64.9) 1.0 NA  1.0 NA 
 45–64  5,429 (20.5) 23 (31.1) 1.5 (0.9–2.5) 0.1  1.9 (1.0–3 6) 0.04 
 >65 3,503 (13.2) 3 (4.1) 0.3 (0.1–0.9) 0.05  0.6 (0.2–2.2) 0.5 
Sex 
    
 
  
 F 10,664 (40.3) 24 (32.4) 1.0  NA  1.0 NA 
 M 15,820 (59.7) 50 (67.6) 1.4 (0.9–2.3) 0.2  1.3 (0.7–2.3) 0.4 
Site of disease 
    
 
  
 Extrapulmonary only 10,069 (38.0) 10 (13.5) 1.0 NA NA  1.0 NA 
 Pulmonary with or  
 without extrapulmonary 
16,443 (62.0) 64 (86.5) 3.9 (2.0–7.6) <0.001  2.7 (1.2–6.0) 0.01 
Initial drug resistance 
    
 
  
 Drug sensitive 24,659 (93.0) 25 (33.8) 1.0  NA  1.0 NA 
 Isoniazid resistance  
 without MDR 
1,446 (5.4) 13 (17.6) 8.9 (4.5–17.4) <0.001  6.5 (2.9–14.4) <0.001 
 Rifampin resistance  
 without MDR 
50 (0.2) 1 (1.4) 19.7 (2.6–148.4) 0.004  14.7 (1.8–123.0) 0.01 
 MDR 363 (1.4) 35 (47.3) 95.1 (56.3–160.5) <0.001  77.3 (39.1–152.8) <0.001 
Country of birth 
    
 
  
 United Kingdom 6,239 (24.6) 21 (29.2) 1.0  NA  1.0 NA 
 China 183 (0.7) 3 (4.2) 4.9 (1.4–16.5) 0.01  2.1 (0.5–9.5) 0.3 
 India 5,470 (21.6) 5 (6.9) 0.3 (0.1–0.7) 0.01  0.3 (0.1–0.8) 0.02 
 Lithuania 181 (0.7) 8 (11.1) 13.3 (5.7–30.0) <0.001  0.6 (0.2–1.8) 0.3 
 Pakistan 3,270 (12.9) 5 (6.9) 0.5 (0.2–1.2) 0.1  0.7 (0.2–2.5) 0.6 
 Somalia 1,191 (4.7) 3 (4.2) 0.8 (0.2–2.5) 0.7  0.6 (0.1–2.7) 0.5 
 South Africa 174 (0.7) 1 (1.4) 1.7 (0.2–12.8) 0.6  1.3 (0.1–11.7) 0.8 
 Nigeria 579 (2.3) 2 (2.8) 1.0 (0.2–4.4) 0.9  0.9 (0.1–6.9) 0.9 
 Other 8,080 (31.8) 24 (33.3) 0.9 (0.5–1.6) 0.7  0.7 (0.3–1.4) 0.3 
Previous TB episode 
    
 
  
 No 23,799 (94.5) 57 (80.3) 1.0  NA  1.0 NA 
 Yes 1,391 (5.5) 14 (19.7) 4.2 (2.3–7.6) <0.001  1.7 (0.8–3.4) 0.2 
Social risk factors 
    
 
  
 0 20,163 (88.4) 47 (72.3) 1.0  NA  1.0  NA 
 >1 2,632 (11.6) 18 (27.7) 2.9 (1.7–5.1) <0.001  1.0 (0.5–2.0) 1.0 
Organism lineage 
    
 
  
 Euro-American 8,631 (39.3) 18 (26.5) 1.0  NA  1.0 NA 
 Central Asian 6,013 (27.4) 9 (13.2) 0.7 (0.3–1.6) 0.4  1.0 (0.4–2.8) 0.9 
 East-African-Indian 3,098 (14.1) 6 (8.8) 0.9 (0.4–2.3) 0.9  1.3 (0.5–3.9) 0.6 
 Beijing 1,230 (5.6) 23 (33.8) 9.0 (4.8–16.7) <0.001  3.4 (1.6–7.4) 0.002 
 Mycobacterium africanum 192 (0.9) 0 NA NA  NA NA 
 M.bovis 124 (0.6) 2 (2.9) 7.7 (1.8-33.7) 0.01  10.3 (2.1–49.8) 0.004 
 Multiple 599 (2.7) 2 (2.9) 1.6 (0.4–7.0) 0.5  1.4 (0.3–6.7) 0.7 
 None 2,076 (9.4) 8 (11.8) 1.8 (0.8–4.3) 0.1  1.9 (0.8–4.9) 0.2 
*aOR, adjusted OR; MDR, multidrug-resistant; NA, not applicable; OR, odds ratio; TB, tuberculosis. 
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therefore the initial specimen should be taken before start-
ing treatment, 37% of patients in our study had a treatment 
start date before the initial specimen collection date. Some 
of these patients may have acquired resistance before the 
initial sample was taken, leading to underestimation of ac-
quired resistance. DST results for ethambutol and pyrazin-
amide often vary between sensitive and resistant because of 
laboratory and biological artifacts. The effect of this vari-
ability is probably minimal because DST was repeated for 
any isolate that showed resistance to these agents. In addi-
tion, our sensitivity analysis, which excluded TB patients 
who acquired resistance to these agents, showed results 
consistent with the original model. Last, other factors, such 
as treatment adherence, may have affected the acquisition 
of resistance, and those factors associated with acquired re-
sistance identified in this study may not be independent of 
adherence; however, adherence data are not routinely col-
lected nationally.
Strategies for reducing drug-resistant TB are being im-
plemented in England and globally (2,3). Whole-genome 
sequencing has been implemented as a diagnostic tool 
throughout the United Kingdom, which may bring further 
insight into the drivers of acquired resistance through iden-
tification of mutations (36). Whole-gene sequencing will 
also improve monitoring of acquired resistance to all drugs, 
first- and second-line, identified for each sample, and will 
reduce variation in results. The World Health Organiza-
tion has endorsed a shorter (9-month) treatment regimen 
for MDR TB, which could potentially improve compliance 
and reduce acquired resistance (37).
These improvements in TB diagnostics and treatment, 
along with the emphasis placed on reducing MDR TB in 
national and global strategies, have increased awareness 
regarding the complex needs of MDR TB patients. Be-
cause the likelihood of acquiring resistance is increased 
among patients with initial drug resistance, these patients 
have a greater need for more specialized facilities and so-
cial services to ensure that appropriate treatment is started 
quickly and monitored thoroughly. Ongoing monitoring of 
the level of acquired drug resistance is one indicator of TB 
control and should be incorporated into routine TB surveil-
lance, especially in countries with higher levels of MDR 
and acquired resistance (27). These results indicate that 
other countries should undertake similar studies to under-
stand risk factors for acquired drug resistance in their own 
countries and to ensure that drug resistance is diagnosed 
and transmission is limited. 
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